Annidis Corp  

(Public, CVE:RHA)   Watch this stock  
Find more results for cve:rha
0.0000 (0.00%)
May 20 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.04 - 0.20
Open     -
Vol / Avg. 0.00/22,359.00
Mkt cap 5.27M
P/E     -
Div/yield     -
EPS -0.06
Shares 117.08M
Beta -1.40
Inst. own     -
Apr 21, 2016
Q4 2015 Annidis Corp Earnings Release (Estimated)

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -599.66% -313.67%
Operating margin -481.33% -238.63%
EBITD margin - -225.16%
Return on average assets -242.72% -229.86%
Return on average equity - -
CDP Score - -


100 Maple Grove Rd
+1-613-5961800 (Phone)
+1-613-5969453 (Fax)

Website links


Annidis Corporation is a Canada-based company, which develops and markets imaging technologies to eye care professionals. The Company has developed a multi-spectral imaging system for retinal and choroidal assessment (the RHA). Its Annidis RHA is an ocular pathology management system to aid in early detection and management of age related macular degeneration (AMD), diabetic retinopathy and glaucoma. Its RHA collects and combines multi-spectral information. The RHA integrates advanced multi-spectral imaging with analytic software for early detection and management of ocular pathologies. The RHA uses multi-spectral imaging to take pictures of the retinal layers of eye. The Company's RHA Gold is used by eye care professionals as a tool for detecting early-onset of eye related diseases such as Dry AMD. The Company's RHA Platinum, which is under development with beta units in clinical testing, allows doctors to visualize choroidal and retinal vasculature non-invasively.

Officers and directors

Gerald Slemko Chairman of the Board
Age: 61
Cameron Bramwell President, Chief Executive Officer
Brian Baker Chief Financial Officer
Michael Francis Crowley Director
Michael Mueller Director
Zeljko Ribaric Director
Ying Zhi Gu Independent Director
Chunhang Yu Independent Director